skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi 5I team,
I am a new member and enjoying your service and advise, so far.
I bought GUD (the dud) back in 2017 @ 9.88 when it was Peters top pick on BNN Market Call. It really hasn't preformed well since and appears to be getting worst. I have read all the questions and answers you've provided and still undecided as to how best to proceed. What is your advise going forward, "hang on" or bail out. Thanks
Homer
Read Answer Asked by Homer on March 08, 2021
Q: I would like your comments on FLGT's Quarter and future guidance. It looked like a blowout to me but the market reaction seems quite muted at the time I am writing this. Guidance is also impressive, calling for revenues of $800m in 2021 a 90% yoy increase after an impressive 2020. FLGT has great margins of around 50%, so 4X next years sales tells us its trading around 8 times next year’s expected earnings….8X forward P/E is what you might expect on a sleepy, slow-growth stock. What am I missing, or is this simply being ignored on a bad market day? A Buy?
Read Answer Asked by Scott on March 06, 2021
Q: I see ABCL is taking it on the chin today down 12% as I type this question. Since about January 1, 2021 I have been considering selling my NVTA and putting the money in ABCL but have done nothing to date. (Procrastination is sometimes the key to success)! NVTA weighting is 1.5%. 2 Questions...
Do you think ABCL has better long term prospects than NVTA and would you be interested in ABCL at +/- $31.50 USD? Or do you think I should use the basket approach and hold both?
Thanks,
Jim
Read Answer Asked by James on March 05, 2021
Q: Could you please comment on VHI's latest licensing deal.
Thanks as always.

VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce a multi-year large-scale licensing transaction of recently acquired subsidiary Intouch with Health’s (“Intouch”) Synopsis product with South Tees Hospitals NHS Foundation Trust (the “Trust” or “South Tees”).

This transaction is among VitalHub’s largest to-date, comprising a 5-year licensing contract for the Company’s proprietary, award-winning Synopsis platform. From initial questionnaire through to post-operative outcomes, Synopsis provides the necessary tools to enable hospitals to manage the entire pre-operative assessment process digitally – removing paper trails, increasing data security, and delivering significant organizational and economic benefits.
Read Answer Asked by karl on March 03, 2021
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!